Cadila Healthcare surges as its arm inks pact with Integrace

Cadila Healthcare is currently trading at Rs. 550.65, up by 4.30 points or 0.79% from its previous closing of Rs. 546.35 on the BSE.

The scrip opened at Rs. 544.30 and has touched a...

Read More

Cadila Healthcare’s arm inks pact with Integrace

Cadila Healthcare’s wholly-owned subsidiary -- Zydus Healthcare has entered into an agreement on September 20, 2021 with Integrace (Purchaser) to sell two brands viz. Mifegest and Cytolog. The said transaction...

Read More

Zydus Cadila receives final approval from USFDA for Vortioxetine Tablets

Zydus Cadila has received final approval from the USFDA to market Vortioxetine Tablets in the strengths of 5 mg, 10 mg, 20 mg (US RLD: Trintellix Tablets). Vortioxetine is used to treat depression. It works by helpi...

Read More

Cadila Healthcare informs about press release

Cadila Healthcare has informed that it enclosed Press release dated September 18, 2021 titled 'Zydus Cadila receives final approval from USFDA for Vortioxetine Tablets’.

Read More

Cadila Healthcare informs about investor conference

Cadila Healthcare has informed that the Company is going to participate in Motilal Oswal Annual Global Investor Conference scheduled on September 14 and 15, 2021.

The abo...

Read More

Cadila Healthcare trades in green on the BSE

Cadila Healthcare is currently trading at Rs. 556.55, up by 1.00 points or 0.18% from its previous closing of Rs. 555.55 on the BSE.

The scrip opened at Rs. 547.50 and has touched a...

Read More

Zydus Cadila gets tentative approval from USFDA for Brexpiprazole Tablets

Zydus Cadila has received tentative approval from the USFDA to market Brexpiprazole Tablets in the strength of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg. (US RLD: Rexulti Tablets). Brexpiprazole is an atypical antipsychotic i...

Read More

Cadila Healthcare informs about press release